Zoetis’ (ZTS) “Hold” Rating Reiterated at BMO Capital Markets

BMO Capital Markets restated their hold rating on shares of Zoetis (NYSE:ZTS) in a research report released on Monday, January 8th.

Several other equities analysts also recently weighed in on the stock. Morgan Stanley raised shares of Zoetis from an equal weight rating to an overweight rating and set a $80.00 price target on the stock in a report on Wednesday, November 29th. Jefferies Group reaffirmed a buy rating on shares of Zoetis in a report on Friday, November 10th. Zacks Investment Research downgraded shares of Zoetis from a buy rating to a hold rating in a report on Wednesday, November 1st. BidaskClub raised shares of Zoetis from a sell rating to a hold rating in a report on Friday, October 13th. Finally, Cantor Fitzgerald set a $80.00 price target on shares of Zoetis and gave the stock a buy rating in a research report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the stock. Zoetis presently has an average rating of Buy and an average target price of $71.94.

Zoetis (ZTS) traded up $0.80 on Monday, hitting $75.39. 1,915,600 shares of the company were exchanged, compared to its average volume of 2,368,844. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The stock has a market capitalization of $36,740.00, a P/E ratio of 39.68, a price-to-earnings-growth ratio of 1.90 and a beta of 1.06. Zoetis has a one year low of $52.00 and a one year high of $75.69.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the firm posted $0.52 earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. research analysts predict that Zoetis will post 2.37 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a dividend of $0.126 per share. This is a boost from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.67%. Zoetis’s payout ratio is 22.11%.

A number of hedge funds have recently bought and sold shares of ZTS. Nisa Investment Advisors LLC lifted its position in Zoetis by 0.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 253,456 shares of the company’s stock worth $18,259,000 after buying an additional 2,180 shares during the period. Daiwa SB Investments Ltd. raised its position in shares of Zoetis by 92.0% during the 4th quarter. Daiwa SB Investments Ltd. now owns 18,152 shares of the company’s stock valued at $1,308,000 after acquiring an additional 8,696 shares during the last quarter. Milestone Resources Group Ltd bought a new stake in shares of Zoetis during the 4th quarter valued at $40,294,000. Chesley Taft & Associates LLC bought a new stake in shares of Zoetis during the 4th quarter valued at $1,027,000. Finally, Hutchens Investment Management Inc raised its position in shares of Zoetis by 15.0% during the 4th quarter. Hutchens Investment Management Inc now owns 13,798 shares of the company’s stock valued at $994,000 after acquiring an additional 1,798 shares during the last quarter. Institutional investors and hedge funds own 93.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zoetis’ (ZTS) “Hold” Rating Reiterated at BMO Capital Markets” was reported by BBNS and is the sole property of of BBNS. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://baseballnewssource.com/markets/zoetis-zts-given-hold-rating-at-bmo-capital-markets/1818427.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.